4-(1-咪唑基)苯甲胺 | 65113-25-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4-(1-咪唑基)苯甲胺
• 中文别名: 1-[4-(1H-咪唑-1-基)苯基]甲胺
• 英文名称: (4-(1H-imidazol-1-yl)phenyl)methanamine
• 英文别名: 4-(imidazol-1-yl)benzylamine；1-[4-(1H-imidazol-1-yl)phenyl]methanamine；(4-imidazol-1-ylphenyl)methanamine
• CAS: 65113-25-9
• 化学式: C₁₀H₁₁N₃
• mdl: MFCD06213154
• 分子量: 173.217
• InChiKey: MACCCEHTOQDLIP-UHFFFAOYSA-N

物化性质

• 沸点：
  345.0±25.0 °C(Predicted)
• 密度：
  1.16±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933290090

反应信息

• 作为反应物：
  描述：

  4-(1-咪唑基)苯甲胺 以 二甲基亚砜 为溶剂， 反应 24.5h， 生成 1-[[[4-(1H-imidazol-1-yl)phenyl]methyl]amino]-3-(2-methylphenoxy)-2-propanol
  参考文献：
  名称：

  Synthesis of novel (aryloxy)propanolamines and related compounds possessing both class II and class III antiarrhythmic activity

  摘要：

  Several (aryloxy)propanolamines and related compounds (i.e. 5-13, 16-18, 20-24, 27-33, 35, 37-39, 41, and 42) were synthesized and investigated for their class III electrophysiological activity and class II (beta-blocking) effects with use of in vitro and in vivo models. Structure-activity relationships are discussed for a series of 30 compounds. A number of these compounds prolonged the action potential duration at 95% repolarization of isolated canine cardiac Purkinje fibers by 20% (C20APD95) at concentrations of less than 1.0 microM, with no significant effects on cardiac conduction. beta-Adrenergic receptor binding studies showed that some of these compounds were 2-20 times more potent for cardiac beta 1 receptors than for beta 2 receptors. In particular, compounds 32, 41, 1, and especially (S)-1 were found to be orally active class III agents in anesthetized mongrel dogs (1 or 3 mg/kg, id) and efficacious at suppressing programmed electrical stimulation induced arrhythmias in halothane-anesthetized dogs. The profile of these compounds was similar to that found for sotalol. Compound (S)-1, which was more potent than sotalol in the PES study and equieffective in the halothane/epinephrine dog model, is being investigated further as a combined class III/II antiarrhythmic agent.

  DOI：

  10.1021/jm00172a033
• 作为产物：
  描述：

  4'-(咪唑-1-基)苯腈 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以80%的产率得到4-(1-咪唑基)苯甲胺
  参考文献：
  名称：

  [EN] PYRAZOLOPYRIMIDINES AS CYCLIN-DEPENDENT KINASE INHIBITORS
  [FR] PYRAZOLOPYRIMIDINES TENANT LIEU D'INHIBITEURS DE KINASES DEPENDANTES DE LA CYCLINE

  摘要：

  在其多种实施方式中，本发明提供了一类新型的吡唑并[1,5-a]嘧啶化合物，作为细胞周期依赖性激酶的抑制剂，以及制备这类化合物的方法，含有一种或多种这类化合物的药物组合物，制备包含一种或多种这类化合物的药物配方的方法，以及利用这类化合物或药物组合物治疗、预防、抑制或改善与CDKs相关的一种或多种疾病的方法。

  公开号：

  WO2004022561A1

文献信息

• [EN] TAM KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASES TAM
  申请人：SYROS PHARMACEUTICALS INC

  公开号：WO2018191587A1

  公开（公告）日：2018-10-18

  Described herein are compounds, methods of making such compounds, compositions (e.g., pharmaceutical compositions/medicaments) that include such compounds, and methods of using such compounds to treat diseases, such as cancer.

  本文描述了化合物，制备这种化合物的方法，包括这种化合物的组合物（例如，包含这种化合物的药物组合物/药物），以及使用这种化合物治疗疾病（如癌症）的方法。
• Transforming Benzylic Amines into Diarylmethanes: Cross-Couplings of Benzylic Pyridinium Salts via C–N Bond Activation
  作者：Jennie Liao、Weiye Guan、Brian P. Boscoe、Joseph W. Tucker、John W. Tomlin、Michelle R. Garnsey、Mary P. Watson

  DOI：10.1021/acs.orglett.8b01062

  日期：2018.5.18

  nickel-catalyzed cross-coupling of benzylic pyridinium salts with arylboronic acids was developed. Coupled with chemoselective pyridinium formation, this method allows benzyl primary amines to be efficiently converted to di(hetero)arylmethanes. Excellent heteroaryl and functional group tolerance is observed, and a one-pot procedure enables benzylic amines to be converted to diarylmethanes directly.

  开发了镍催化的苄基吡啶鎓盐与芳基硼酸的交叉偶联。结合化学选择性吡啶鎓的形成，该方法可使苄基伯胺有效地转化为二（杂）芳基甲烷。观察到优异的杂芳基和官能团耐受性，一锅法可使苄基胺直接转化为二芳基甲烷。
• [EN] 5-ALKYLTHIO-7-[(4-ARYLBENZYL)AMINO]-1(2)H-PYRAZOLO[4,3-D]PYRIMIDINES FOR TREATMENT OF LYMPHOMA<br/>[FR] 5-ALKYLTHIO-7-[(4-ARYLBENZYL) AMINO] -1 (2) H-PYRAZOLO [4,3-D] PYRIMIDINES POUR LE TRAITEMENT DU LYMPHOME
  申请人：UNIV PALACKEHO

  公开号：WO2019149295A1

  公开（公告）日：2019-08-08

  The present invention relates to 5-alkylthio-7-[(4-arylbenzyl)amino]-1(2)H-pyrazolo[4,3-d]pyrimidine derivatives of formula I which are effective inhibitors of kinases and exhibit strong antiproliferative and proapoptotic properties on lymphoma cells. This invention further relates to use of said derivatives in the treatment of blood hyperproliferative diseases, such as Non-Hodgkin lymphomas.

  本发明涉及式I的5-烷基硫基-7-[(4-芳基苄基)氨基]-1(2)H-吡唑并[4,3-d]嘧啶衍生物，它们是激酶的有效抑制剂，并在淋巴瘤细胞上表现出强烈的抗增殖和促凋亡特性。本发明还涉及利用这些衍生物治疗血液过度增殖性疾病，如非霍奇金淋巴瘤。
• [EN] 2,4,6-TRISUBSTITUTED PYRIDO (3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS<br/>[FR] PYRIDO(3,2-D)PYRIMIDINES TRISUBSTITUÉES EN POSITION 2,4,6 UTILES POUR TRAITER DES INFECTIONS VIRALES
  申请人：GILEAD SCIENCES INC

  公开号：WO2010002998A1

  公开（公告）日：2010-01-07

  Pyrido(3,2-d)pyrimidine derivatives represented by the structural formuia (Ia): wherein, R1, R2 and R3 are defined herein, pharmaceutical acceptable addition salts, stereochemical isomeric forms, N-oxides, solvates and pro-drugs thereof, for use in the treatment of hepatitis C.

  Pyrido(3,2-d)pyrimidine衍生物由结构式(Ia)表示：其中，R1、R2和R3在此处定义，其药用可接受的盐、立体化学异构体形式、N-氧化物、溶剂合物及其前药，用于治疗丙型肝炎。
• Synthesis and Structure–Activity Relationship Studies of <i>N</i>-Benzyl-2-phenylpyrimidin-4-amine Derivatives as Potent USP1/UAF1 Deubiquitinase Inhibitors with Anticancer Activity against Nonsmall Cell Lung Cancer
  作者：Thomas S. Dexheimer、Andrew S. Rosenthal、Diane K. Luci、Qin Liang、Mark A. Villamil、Junjun Chen、Hongmao Sun、Edward H. Kerns、Anton Simeonov、Ajit Jadhav、Zhihao Zhuang、David J. Maloney

  DOI：10.1021/jm5010495

  日期：2014.10.9

  screen of >400000 compounds and subsequent medicinal chemistry optimization of small molecules that inhibit the deubiquitinating activity of USP1/UAF1. Ultimately, these efforts led to the identification of ML323 (70) and related N-benzyl-2-phenylpyrimidin-4-amine derivatives, which possess nanomolar USP1/UAF1 inhibitory potency. Moreover, we demonstrate a strong correlation between compound IC50 values

  泛素缀合或解缀合的失调与包括癌症在内的许多人类疾病的发病机制有关。去泛素化酶 USP1（泛素特异性蛋白酶 1）与 UAF1（USP1 相关因子 1）结合，是已知的 DNA 损伤反应调节剂，并已被证明是有希望的抗癌靶点。为了进一步评估 USP1/UAF1 作为治疗靶点，我们对超过 400000 种化合物进行了定量高通量筛选，并随后对抑制 USP1/UAF1 去泛素化活性的小分子进行了药物化学优化。最终，这些努力导致鉴定出 ML323 ( 70 ) 和相关的N-benzyl-2-phenylpyrimidin-4-amine 衍生物，具有纳摩尔 USP1/UAF1 抑制效力。此外，我们证明了USP1/UAF1 抑制的化合物 IC 50值与非小细胞肺癌细胞的活性之间存在很强的相关性，特别是单泛素化 PCNA (Ub-PCNA) 水平增加和细胞存活率降低。我们的结果确定了 USP1/UAF1 去泛